Dear Ms. Fleming:

Please refer to your Supplemental New Drug Application (sNDA) dated and received May 11, 2018, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for MiraLAX (polyethylene glycol 3350) powder for solution, 17 g per sachet.

This “Prior Approval” sNDA provides for a new shrink-wrapped twin pack configuration consisting of an outer open-top carton holding two 20-count cartons (alternative A or alternative B).

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

**LABELING**

Submit final printed labeling (FPL), as soon as they are available, but no more than 30 days after they are printed. The FPL must be identical to the labeling submitted below, and must be in the “Drug Facts” format (21 CFR 201.66), where applicable.

<table>
<thead>
<tr>
<th>Submitted Labeling</th>
<th>Date Submitted</th>
</tr>
</thead>
<tbody>
<tr>
<td>40-count “twin pack” outer carton (holds two 20-count cartons)</td>
<td>June 14, 2018</td>
</tr>
<tr>
<td>20-count carton (alternative Die Line A presentation)</td>
<td>May 11, 2018</td>
</tr>
<tr>
<td>20-count carton (alternative Die Line B presentation)</td>
<td>July 19, 2018</td>
</tr>
<tr>
<td>1x17 g immediate container (sachet)</td>
<td>July 19, 2018</td>
</tr>
</tbody>
</table>
The FPL should be submitted electronically according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format — Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (April 2017, Revision 4)*. For administrative purposes, designate this submission “**Final Printed Labeling for approved NDA 022015/S-034.**” Approval of this submission by FDA is not required before the labeling is used.

**DRUG REGISTRATION AND LISTING**

All drug establishment registration and drug listing information is to be submitted to FDA electronically, via the FDA automated system for processing structured product labeling (SPL) files (eLIST). At the time that you submit your final printed labeling (FPL), the content of labeling (Drug Facts) should be submitted in SPL format as described at [http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm](http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm). Information on submitting SPL files using eLIST may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at [http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf](http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf). In addition, representative container or carton labeling, whichever includes Drug Facts, (where differences exist only in the quantity of contents statement) should be submitted as a JPG file.

**REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Alina Salvatore, Regulatory Project Manager, at (240) 402-0379.

Sincerely,

{See appended electronic signature page}

Karen Murry Mahoney, MD, FACE
Deputy Director
Division of Nonprescription Drug Products
Office of Drug Evaluation IV
Center for Drug Evaluation and Research

ENCLOSURE(S):
Carton and Container Labeling
This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

KAREN M MAHONEY
10/12/2018